All In Biotech

NDA 217369 · Biogen

Zurzuvae

Zuranolone · Oral · Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

NovelPriority review

CDER novel approval, Aug 4, 2023: To treat postpartum depression

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Aug 4, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

15

8 Phase 3, 2 recruiting

FAERS reports

1,940

306 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects [see Warnings and Precautions ( 5.1 , 5.2 )] . Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE [see Warnings and Precautions ( 5.1 )] . WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES See full prescribing information for complete boxed warning. ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not to drive or engage in other potentially hazardous...

What it is approved for

From the label in effect Jun 15, 2026.

ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adults. ( 1 )

Mechanism: The mechanism of action of zuranolone in the treatment of PPD is not fully understood but is thought to be related to its positive allosteric modulation of GABA A receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 13, 2026 Supplement 4 · Efficacy · priority review Label
  • Aug 4, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
3 products under this application
  • ZURZUVAE · ZURANOLONE 30MG · CAPSULE, ORAL · Prescription
  • ZURZUVAE · ZURANOLONE 20MG · CAPSULE, ORAL · Prescription
  • ZURZUVAE · ZURANOLONE 25MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Zuranolone" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • somnolence637
  • dizziness368
  • fatigue299
  • anxiety151
  • sedation150
  • feeling abnormal139
  • suicidal ideation112
  • tremor106
  • feeling drunk91
  • depression86
  • nausea79
  • memory impairment74

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20231
2024379
2025753
2026807

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zurzuvae (Zuranolone)

2024 spending

$544K

Beneficiaries

34

34 claims

Per beneficiary

$16,013

$571.90 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$544,445

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 33 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.